GlassScriptPhysician profile
Ramsha Malik
NPI 1043662984
$9,633.79
in general payments reported to CMS, 2019-2025
29 companies · $4,005 in 2025
The $4,005 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $250 · 2023: $984 · 2024: $4,394 · 2025: $4,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,357 · Travel and Lodging: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,356.97 |
| Travel and Lodging | $1,026.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,686.52 | 2023-2025 | |
| Livanova USA, INC. | $1,392.38 | 2024 | Vns Therapy |
| Pfizer INC. | $788.31 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $644.30 | 2024-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $559.95 | 2022-2025 | Ultomiris |
| Biogen, INC. | $412.65 | 2023-2025 | Vumerity, Leqembi, Tysabri |
| Ucb, INC. | $408.92 | 2023-2025 | Nayzilam, Briviact, Zilbrysq |
| Genentech USA, INC. | $404.30 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Novartis Pharmaceuticals Corporation | $377.33 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $344.81 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $324.61 | 2023-2025 | Rexulti, Nuedexta |
| Mdd US Operations, LLC | $298.56 | 2024-2025 | Gocovri |
| Tg Therapeutics, INC. | $280.23 | 2024-2025 | |
| Eisai INC. | $268.95 | 2023-2025 | |
| Argenx US, INC. | $264.93 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $193.16 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Sk Life Science, INC. | $181.98 | 2022-2025 | Xcopri |
| Mallinckrodt Hospital Products INC. | $174.77 | 2024-2025 | Acthar |
| Amneal Pharmaceuticals LLC | $139.33 | 2023-2025 | Rytary, Crexont |
| Lundbeck LLC | $109.53 | 2024-2025 | Rexulti, Vyepti |
| Genzyme Corporation | $81.59 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $61.07 | 2023-2024 | Austedo Xr, Austedo |
| Merz Pharmaceuticals, LLC | $59.78 | 2025 | Ampyra, Inbrija, Xeomin |
| Janssen Biotech, INC. | $48.72 | 2025 | |
| Neurelis, INC. | $33.37 | 2025 | Valtoco |
| Amgen INC. | $29.42 | 2024-2025 | Uplizna |
| Axsome Therapeutics, INC. | $25.65 | 2025 | Symbravo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.75 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $17.92 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramsha Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.